Bar Harbor BioTechnology, Inc. Licenses PCR and Real-Time PCR Patents From Life Technologies AG

Published: Feb 16, 2010

TRENTON, ME--(Marketwire - February 16, 2010) -

Highlighted Links

Bar Harbor BioTechnology, Inc. (BHB) announced today that it has entered into a license agreement with Life Technologies. Under the agreement, BHB will offer contract research services that provide data collection and analysis based on the StellARray™ and XenoQ™ systems. Researchers in the life sciences field can now contract BHB to run their Real-Time PCR experiments.

"We wanted to make our expertise in assay design available to all genetic researchers and provide excellent quality data," stated Robert Phelps, CEO of Bar Harbor BioTechnology. Researchers would purchase StellARrays™ or XenoQ™ Assays through their exclusive distributor, Lonza Corporation, and then contract BHB to perform the Real-Time PCR services.

The data generated in the experiments will be analyzed using the Global Pattern Recognition™ (GPR) analysis software, which is exclusive to BHB. "GPR has been instrumental in some rather significant discoveries," says Dan Shaffer, VP of Product Development for Bar Harbor BioTechnology. "We believe there are many laboratories that do not have the resources to utilize our technology. We wanted to change that and make it easier for all labs to make use of our systems."

Bar Harbor BioTechnology has expanded the staff of the company to provide the new services secured in this agreement. "We have been very fortunate to have fantastic support from the State of Maine and our community. This new expansion was part of a strategic plan to create new high tech jobs here in Maine," reported Robert Phelps. "We are very proud that we were in a position to do just that."

About Bar Harbor BioTechnology, Inc.

Bar Harbor BioTechnology, Inc. is a privately held company founded in 2006 and located in the downeast section of Maine. The company launched its flagship products, GeneSieve™, StellARray™ and Global Pattern Recognition™ in 2007. The StellARray™ and XenoQ™ systems are distributed by Lonza Corporation under an exclusive global distribution agreement that was created in 2008. The StellARray™ system was recently used to identify a drug that shows the reversal of Type 1 Diabetes in mouse models.

For more information, please contact Robert Phelps at: robert.phelps@barharborbio.com

http://www.bhbio.com/

Bar Harbor BioTechnology Inc. undertakes no obligation to release publicly the results of any revisions to any forward-looking statement made or implied in this release, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Statements in this release should be evaluated accordingly.